Conference Correspondent
Radius Health, Inc. (Nasdaq:RDUS) today provided an update on data from the Phase 1 005 clinical study of elacestrant (RAD1901), an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+) breast cancer. The data were presented at a Spotlight Presentation (Abstract 1410) during the 2017 San Antonio Breast Cancer Symposium (SABCS). Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration. Read More ›
The combination of abemaciclib plus anastrozole is superior to anastrozole alone in reducing Ki67 across a spectrum of subgroups of patients with hormone receptor (HR)-positive, HER2-negative breast cancer.
Read More ›
Abemaciclib, but not ribociclib or palbociclib, exhibits inhibition of CDK4/6 plus kinases other than CDK4/6, and induces cell death rather than cytostasis, which may be therapeutically advantageous in patients with hormone receptor‒positive breast cancer that is generally resistant to CDK4/6 inhibitors. Read More ›
Researchers have identified a CDK4/6 inhibitor–sensitive E2F4 gene expression signature in estrogen receptor (ER)-positive breast cancers resistant to aromatase inhibitors that can potentially identify patients with ER-positive breast cancer who are candidates for adjuvant therapy with CDK4/6 inhibitors in combination with antiestrogens.
Read More ›
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA-approved for HR+ metastatic breast cancer, from ribociclib and palbociclib. Read More ›
Dr Hope Rugo provides an overview of some hot topics being covered at SABCS 2017 in the areas of hormone therapy, immunotherapy, neoadjuvant therapy, and more. Read More ›
Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2+ breast cancer. Read More ›
Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor. Read More ›
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer. Read More ›
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy. Read More ›